Legal & General Group Plc acquired a new position in shares of Calumet, Inc. (NASDAQ:CLMT – Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 48,140 shares of the oil and gas company’s stock, valued at approximately $1,734,000. Legal & General Group Plc owned 0.06% of Calumet at the end of the most recent quarter.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Islay Capital Management LLC bought a new position in Calumet in the 4th quarter worth $25,000. Aster Capital Management DIFC Ltd boosted its holdings in Calumet by 294.7% during the fourth quarter. Aster Capital Management DIFC Ltd now owns 1,646 shares of the oil and gas company’s stock valued at $33,000 after acquiring an additional 1,229 shares during the period. Global Retirement Partners LLC acquired a new stake in shares of Calumet in the fourth quarter valued at about $34,000. Covestor Ltd grew its position in shares of Calumet by 29.1% in the fourth quarter. Covestor Ltd now owns 2,180 shares of the oil and gas company’s stock valued at $43,000 after purchasing an additional 492 shares during the last quarter. Finally, Advisory Services Network LLC bought a new position in shares of Calumet in the third quarter worth about $59,000. 34.41% of the stock is currently owned by institutional investors and hedge funds.
Calumet Price Performance
Calumet stock opened at $53.13 on Monday. The business has a 50 day moving average price of $43.76 and a two-hundred day moving average price of $36.26. The stock has a market cap of $4.67 billion, a price-to-earnings ratio of -34.28 and a beta of 0.72. Calumet, Inc. has a 12 month low of $16.75 and a 12 month high of $54.69.
Key Calumet News
Here are the key news stories impacting Calumet this week:
- Positive Sentiment: HC Wainwright raised its earnings forecasts and maintained a Buy rating. The firm increased its Q3 2026 EPS estimate to $0.62 from $0.60, Q4 to $0.24 from $0.22, FY2026 to $0.17 from $0.12, and FY2027 to $1.11 from $0.59. Its $75 price target implies substantial upside from the stock’s recent trading level. HC Wainwright earnings estimate report
- Positive Sentiment: The upward revisions suggest HC Wainwright expects stronger profitability over the next several quarters, potentially reflecting improved operating performance or business conditions. The revised FY2027 forecast is notably above the broader current-year consensus estimate of $0.46 per share. Calumet stock price expected to rise
- Neutral Sentiment: Calumet announced plans to attend the H.C. Wainwright conference. The event could provide investors with updates on strategy and operations, but no new financial information was disclosed in the announcement. Calumet conference announcement
- Neutral Sentiment: A Zacks analysis compared Calumet’s year-to-date performance with TXO Partners and the broader oil-and-energy sector. The article provides relative-performance context but does not indicate a new company-specific catalyst. Zacks Calumet sector performance analysis
- Negative Sentiment: Pomerantz LLP announced an investigation into potential claims on behalf of Calumet investors. Although the announcement does not establish wrongdoing, the prospect of litigation or regulatory concerns may weigh on sentiment and introduce uncertainty. Pomerantz investor investigation
Insider Buying and Selling
In other Calumet news, Director Daniel Sajkowski sold 4,240 shares of Calumet stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $36.16, for a total transaction of $153,318.40. Following the sale, the director owned 77,718 shares in the company, valued at $2,810,282.88. The trade was a 5.17% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 3.15% of the stock is currently owned by company insiders.
Analyst Upgrades and Downgrades
Several research firms recently weighed in on CLMT. Citigroup reissued a “buy” rating on shares of Calumet in a research report on Monday, August 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Calumet in a research report on Friday, August 7th. UBS Group upped their price target on Calumet from $26.00 to $47.00 and gave the stock a “neutral” rating in a report on Tuesday, August 25th. The Goldman Sachs Group increased their price objective on Calumet from $40.00 to $45.00 and gave the company a “neutral” rating in a research report on Tuesday, August 18th. Finally, HC Wainwright raised their price objective on shares of Calumet from $60.00 to $75.00 and gave the stock a “buy” rating in a research note on Wednesday, September 2nd. Two equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Calumet currently has a consensus rating of “Hold” and an average price target of $51.75.
Check Out Our Latest Analysis on Calumet
Calumet Company Profile
Calumet Specialty Products Partners, L.P. (NASDAQ: CLMT) is an independent provider of high-value, essential product solutions derived from both petroleum and renewable feedstocks. The company operates an integrated network of manufacturing plants, blending terminals and storage facilities across North America, delivering customized products and technical services to industrial, automotive, consumer and agricultural end markets. By leveraging its scale and technical expertise, Calumet tailors supply chain and formulation solutions to meet stringent regulatory and performance requirements.
Calumet’s product portfolio includes specialty lubricants and base oils for high-performance applications; process oils and waxes for food-grade, cosmetic and packaging uses; industrial solvents and cleaning solutions; and fuel additives designed to optimize engine performance and emissions.
Featured Articles
- Five stocks we like better than Calumet
- AI Token Costs Are Changing the Hardware vs. Software Debate
- 3 ETFs That Could Move as Rate Expectations Shift
- 3 Stocks With September Catalysts Investors Shouldn’t Ignore
- Ollie’s Bargain Outlet Stock Falls on Weak Comps Despite Margin Gains
Want to see what other hedge funds are holding CLMT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Calumet, Inc. (NASDAQ:CLMT – Free Report).
Receive News & Ratings for Calumet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calumet and related companies with MarketBeat.com's FREE daily email newsletter.
